Bellevue Group’s Labcorp LH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $78.4K | Hold |
280
| – | – | ﹤0.01% | 135 |
|
|
2026
Q1 | $74.7K | Sell |
280
-5,389
| -95% | -$1.46M | ﹤0.01% | 143 |
|
|
2025
Q4 | $1.42M | Sell |
5,669
-9,396
| -62% | -$2.5M | 0.03% | 105 |
|
|
2025
Q3 | $4.32M | Sell |
15,065
-21,627
| -59% | -$5.79M | 0.09% | 80 |
|
|
2025
Q2 | $9.63M | Buy |
36,692
+8,551
| +30% | +$2.08M | 0.21% | 65 |
|
|
2025
Q1 | $6.55M | Buy |
28,141
+27,925
| +12,928% | +$6.78M | 0.15% | 79 |
|
|
2024
Q4 | $49.5K | Buy |
216
+10
| +5% | +$2.29K | ﹤0.01% | 160 |
|
|
2024
Q3 | $46K | Buy |
206
+16
| +8% | +$3.52K | ﹤0.01% | 162 |
|
|
2024
Q2 | $38.7K | Buy |
190
+42
| +28% | +$8.54K | ﹤0.01% | 165 |
|
|
2024
Q1 | $32.3K | Sell |
148
-6,941
| -98% | -$1.53M | ﹤0.01% | 167 |
|
|
2023
Q4 | $1.61M | Buy |
7,089
+101
| +1% | +$21.2K | 0.02% | 111 |
|
|
2023
Q3 | $1.4M | Sell |
6,988
-1,146
| -14% | -$242K | 0.02% | 118 |
|
|
2023
Q2 | $1.69M | Hold |
8,134
| – | – | 0.02% | 117 |
|
|
2023
Q1 | $1.6M | Buy |
8,134
+4,258
| +110% | +$876K | 0.02% | 120 |
|
|
2022
Q4 | $784K | Sell |
3,876
-664
| -15% | -$130K | 0.01% | 142 |
|
|
2022
Q3 | $799K | Sell |
4,540
-407
| -8% | -$83.3K | 0.01% | 140 |
|
|
2022
Q2 | $996K | Hold |
4,947
| – | – | 0.01% | 137 |
|
|
2022
Q1 | $1.12M | Sell |
4,947
-4,889
| -50% | -$1.15M | 0.01% | 145 |
|
|
2021
Q4 | $2.65M | Sell |
9,836
-41,496
| -81% | -$10.3M | 0.03% | 141 |
|
|
2021
Q3 | $12.4M | Buy |
51,332
+9,195
| +22% | +$2.32M | 0.13% | 110 |
|
|
2021
Q2 | $9.99M | Buy |
42,137
+25,608
| +155% | +$5.83M | 0.1% | 125 |
|
|
2021
Q1 | $3.62M | Sell |
16,529
-5,625
| -25% | -$1.13M | 0.04% | 133 |
|
|
2020
Q4 | $3.87M | Sell |
22,154
-40,974
| -65% | -$7.08M | 0.04% | 131 |
|
|
2020
Q3 | $10.2M | Hold |
63,128
| – | – | 0.14% | 107 |
|
|
2020
Q2 | $9.01M | Buy |
63,128
+42,338
| +204% | +$5.86M | 0.13% | 112 |
|
|
2020
Q1 | $2.26M | Buy |
20,790
+14,358
| +223% | +$2.07M | 0.04% | 128 |
|
|
2019
Q4 | $935K | Sell |
6,432
-55
| -0.8% | -$7.94K | 0.01% | 150 |
|
|
2019
Q3 | $936K | Sell |
6,487
-244
| -4% | -$35.6K | 0.02% | 146 |
|
|
2019
Q2 | $1M | Sell |
6,731
-73
| -1% | -$10.2K | 0.02% | 140 |
|
|
2019
Q1 | $894K | Sell |
6,804
-762
| -10% | -$93.9K | 0.05% | 127 |
|
|
2018
Q4 | $821K | Sell |
7,566
-101,897
| -93% | -$13.7M | 0.05% | 121 |
|
|
2018
Q3 | $16.3M | Buy |
109,463
+21,884
| +25% | +$3.33M | 1.04% | 31 |
|
|
2018
Q2 | $13.5M | Buy |
87,579
+18,053
| +26% | +$2.73M | 1.15% | 31 |
|
|
2018
Q1 | $9.66M | Buy |
69,526
+3,388
| +5% | +$498K | 0.96% | 40 |
|
|
2017
Q4 | $9.06M | Buy |
66,138
+2,490
| +4% | +$329K | 0.95% | 42 |
|
|
2017
Q3 | $8.26M | Buy |
63,648
+3,853
| +6% | +$514K | 0.86% | 42 |
|
|
2017
Q2 | $7.92M | Buy |
59,795
+44,663
| +295% | +$5.47M | 0.94% | 44 |
|
|
2017
Q1 | $1.86M | Buy |
15,132
+5,820
| +63% | +$689K | 0.25% | 81 |
|
|
2016
Q4 | $1.03M | Hold |
9,312
| – | – | 0.21% | 85 |
|
|
2016
Q3 | $1.1M | Hold |
9,312
| – | – | 0.2% | 92 |
|
|
2016
Q2 | $1.04M | Sell |
9,312
-2,328
| -20% | -$251K | 0.2% | 95 |
|
|
2016
Q1 | $1.17M | Buy |
+11,640
| New | +$1.12M | 0.21% | 94 |
|
Other funds holding LH
Bellevue Group's LH Position: Q2 2026 in Review
Bellevue Group held its Labcorp (LH) position steady in Q2 2026 at 280 shares worth $78.4K. The position accounts for ﹤0.01% of the portfolio, ranked #135.
Bellevue Group first reported a position in LH in Q1 2016 and has held it in 42 quarters since. The position peaked at $16.3M in Q3 2018. 1,051 funds tracked by Wall St. Rank hold LH as of Q2 2026.
- Bellevue Group held 280 shares of Labcorp worth $78.4K as of Q2 2026.
- Bellevue Group left its Labcorp share count unchanged in Q2 2026.
- Labcorp made up ﹤0.01% of Bellevue Group's portfolio in Q2 2026, its #135 holding.
- Bellevue Group first reported a position in Labcorp in Q1 2016 and has held it in 42 quarters since.
- Bellevue Group's Labcorp position peaked at $16.3M in Q3 2018.
- 1,051 funds tracked by Wall St. Rank held Labcorp as of Q2 2026.
Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.